Strategies for prevention of anthracycline cardiotoxicity

Young, 1981, The anthracycline antineoplastic drugs, N. Engl. J. Med., 305, 153, 10.1056/NEJM198107163050305

Bristow, 1978, Early anthracycline cardiotoxicity, Am. J. Med., 65, 823, 10.1016/0002-9343(78)90802-1

Tan, 1967, Daunomycin, an antitumor antibiotic in the treatment of neoplastic disease, Cancer, 20, 333, 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K

Jaenke, 1976, Delayed and progressive myocardial lesions after adriamycin administration in the rabbit, Cancer Res., 36, 2958

Lenaz, 1976, Cardiotoxicity of adriamycin and related anthracyclines, Cancer Treat. Rev., 3, 111, 10.1016/S0305-7372(76)80018-7

Unverferth, 1985, Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs, Am. J. Cardiol., 56, 157, 10.1016/0002-9149(85)90585-5

Waravdakar, 1982, Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds, Adv. Pharmac. Chemother., 19, 249, 10.1016/S1054-3589(08)60025-3

Young, 1975, Pathological effects of adriamycin in experimental systems, Cancer Chemother. Rep., 6, 159

Davies, 1986, Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase, J. Biol. Chem., 261, 3060, 10.1016/S0021-9258(17)35746-0

Doroshow, 1983, Effect of anthracycline antibiotics on oxygen radical formation in rat heart, Cancer Res., 43, 460

Doroshow, 1986, Redox cycling of anthracyclines by cardiac mitochondria, J. Biol. Chem., 261, 3068, 10.1016/S0021-9258(17)35747-2

Goodman, 1977, Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin, Biochem. Biophys. Res. Commun., 77, 797, 10.1016/S0006-291X(77)80048-X

Mimnaugh, 1983, Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs; characterization and effects of reactive oxygen scavengers, J. Pharmacol. Exp. Ther., 226, 806

Olson, 1981, Mechanism of adriamycin cardiotoxicity; evidence for oxidative stress, Life Sci., 29, 1393, 10.1016/0024-3205(81)90001-1

Olson, 1990, Doxorubicin cardiotoxicity: analysis of prevailing hypotheses, FASEB J., 4, 3076, 10.1096/fasebj.4.13.2210154

Bachur, 1978, A general mechanism for microsomal activation of quinone anticancer agents to free radicals, Cancer Res., 38, 1745

Thayer, 1977, Adriamycin stimulated superoxide formation in submitochondrial particles, Chem-Biol. Inter., 19, 265, 10.1016/0009-2797(77)90050-3

Doroshow, 1979, The effect of doxorubicin on hepatic and cardiac glutathione, Res. Commun. Chem. Pathol. Pharmacol., 26, 285

Bachur, 1977, Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation, Mol. Pharmacol., 13, 901

Mimnaugh, 1982, Differential effects of anthracycline drugs on rat heart and liver microsomal reduced nicotinamide adenine dinucleotide phosphate- dependent lipid peroxidation, Cancer Res., 42, 3574

Mimnaugh, 1983, Enhancement of rat heart microsomal lipid peroxidation following doxorubicin treatment in vivo, Cancer Treat. Rep., 67, 731

Mimnaugh, 1985, Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin, Biochem. Pharmacol., 34, 847, 10.1016/0006-2952(85)90766-X

Mimnaugh, 1985, Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei, Cancer Res., 45, 3296

Myers, 1977, Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response, Science, 197, 165, 10.1126/science.877547

Gianni, 1985, Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen, J. Biol. Chem., 260, 6820, 10.1016/S0021-9258(18)88854-8

Giannai, 1980, Role of daunosamine and hydroxy acetyl side chain in reaction with iron and lipid peroxidation, J. Natl. Cancer Inst., 80, 1104, 10.1093/jnci/80.14.1104

Muindi, 1984, Hydroxyl radical production and DNA damage induced by anthracycline-iron complex, FEBS Lett., 172, 226, 10.1016/0014-5793(84)81130-8

Muindi, 1985, Thiol-dependent DNA damage produced by anthracycline-iron complexes, 27, 356

Myers, 1982, Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex, Biochemistry, 21, 1707, 10.1021/bi00537a001

Sugioka, 1983, Generation of hydroxyl radicals during the enzymatic reductions of the Fe3+-ADP-phosphate-adriamycin and Fe3+-ADP-EDTA systems, Biochem. Biophys. Acta., 753, 411, 10.1016/0005-2760(83)90065-6

Zweier, 1986, Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of sidechain hydroxyl group, Biochem. Biophys. Acta., 884, 326, 10.1016/0304-4165(86)90181-9

Mimnaugh, 1981, Stimulation by adriamycin of rat heart and liver microsomal NADPH-Cytochrome P-450 reductase, Biochem. Pharmacol., 30, 2797, 10.1016/0006-2952(81)90417-2

Jaenke, 1974, An anthracycline antibiotic-induced cardiomyopathy in rabbits, Lab. Invest., 30, 292

Olson, 1977, Subacute cardiotoxicity of adriamycin in the rat, Lab. Invest., 37, 386

Benedetti, 1984, Cytotoxic aldehydes originating from the peroxidation of liver microsomal lipids, 792, 172

Green, 1992, ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies, 101

Beraldo, 1985, Iron (III)-adriamycin and iron (III)daunorubicin complexes: physiochemical characteristics, interactions with DNA, and antitumor activity, Biochemistry, 24, 284, 10.1021/bi00323a007

Myers, 1986, Role of iron in adriamycin biochemistry, 45, 2792

Gutteridge, 1983, Adriamycin-iron catalyzed phospholipid peroxide: a reaction not involving reduced adriamycin or hydroxyl radicals, Biochem. Pharmacol., 32, 1949, 10.1016/0006-2952(83)90065-5

Minotti, 1987, The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide, J. Biol. Chem., 262, 1098, 10.1016/S0021-9258(19)75755-X

Sugioka, 1982, Mechanisms of phospholipid peroxidation induced by ferric iron-ADP adriamycin coordination complex, Biochem. Biophys. Acta., 713, 333, 10.1016/0005-2760(82)90251-X

Demant, 1984, Binding of adriamycin-Fe3+ complex to membrane phospholipids, Eur. J. Biochem., 142, 571, 10.1111/j.1432-1033.1984.tb08324.x

Capaldi, 1982, Structural and functional features of the interaction of cyochrome c with complex III and cytochrome c oxidase, FEBS Lett., 138, 1, 10.1016/0014-5793(82)80382-7

Demant, 1984, Transfer of ferritin-bound iron to adriamycin, FEBS Lett, 176, 97, 10.1016/0014-5793(84)80919-9

Ruggeri, 1984, Studies of human isoferritins in tissues and body fluids, 67

Harrison, 1980, Ferritin structure and function, 130

Vile, 1988, Adriamycin-dependent peroxidation of rat liver and heart microsomes catalysed by iron chelates and ferritin, Biochem. Pharmacol, 37, 2893, 10.1016/0006-2952(88)90273-0

Thomas, 1986, Release of iron from ferritin by cardiotoxic anthracycline antibiotics, Arch. Biochem. Biophys., 248, 684, 10.1016/0003-9861(86)90523-0

Doroshow, 1980, Enzymatic defenses of the mouse heart against reactive oxygen metabolites, J. Clin. Invest., 65, 128, 10.1172/JCI109642

Julicher, 1986, The role of lipid perodixation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart, J. Pharm. Pharmac., 38, 277, 10.1111/j.2042-7158.1986.tb04566.x

Kanter, 1985, Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin, J. Appl. Physiol, 59, 1298, 10.1152/jappl.1985.59.4.1298

Adachi, 1983, Relation between cardiotoxic effects of adriamycin and superoxide anion radical, J. Pharmacoliodyn., 6, 114, 10.1248/bpb1978.6.114

Alderton, 1990, Role of (±)-1,2-Bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy, Cancer Res., 50, 5136

Porta, 1983, Acute adriamycin cardiotoxicity in rats, Res. Comm. Chem. Path. Pharmac., 41, 125

Billingham, 1978, Anthracycline cardiomyopathy monitored by morphological changes, Cancer Treat. Rep., 62, 865

Blum, 1974, Adriamycin: A new anticancer drug with significant clinical activity, Ann. Intern. Med., 80, 249, 10.7326/0003-4819-80-2-249

Bristow, 1978, Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization, Ann. Intern. Med., 88, 168, 10.7326/0003-4819-88-2-168

Torti, 1986, Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy, Cancer Res., 46, 3722

Buzdar, 1985, Early and delayed clinical cardiotoxicity of doxorubicin, Cancer, 55, 2761, 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P

Haq, 1985, Doxorubicin-induced congestive heart failure in adults, Cancer, 56, 1361, 10.1002/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S

Von Hoff, 1979, Risk factors for doxorubicin-induced congestive heart failure, Ann. Intern. Med., 91, 710, 10.7326/0003-4819-91-5-710

Freter, 1986, Doxorubicin cardiac toxicity manifesting seven years after treatment, Am. J. Med., 80, 483, 10.1016/0002-9343(86)90724-2

Lipschultz, 1991, Late effects for doxorubicin therapy for acute lymphoblastic leukemia in childhood, N. Engl. J. Med., 324, 808, 10.1056/NEJM199103213241205

Minow, 1977, Adriamycin cardiomyopathyrisk factors, Cancer, 39, 1397, 10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U

Cortes, 1975, Adriamycin (NSC-123127) cardiotoxicity: a clinicopathological correlation, Cancer Chemother. Rep., 6, 215

Gilladoga, 1976, The cardiotoxicity of adriamycin and daunomycin in children, Cancer, 37, 1070, 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6

Goorin, 1981, Congestive heart failure due to adriamycin in children, Cancer, 47, 2810, 10.1002/1097-0142(19810615)47:12<2810::AID-CNCR2820471210>3.0.CO;2-4

Saini, 1987, Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity, Ann. Intern. Med., 106, 814, 10.7326/0003-4819-106-6-814

Schwartz, 1987, Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven year experience using radionuclide angiocardiography, Am. J. Med., 82, 1109, 10.1016/0002-9343(87)90212-9

Bonnadonna, 1975, Adriamycin (NSC-123127) studies at the Instituto Nazionale Tumori, Cancer Chemother. Rep., 6, 213

Lefrak, 1973, A clinicopathologic analysis of adriamycin cardiotoxicity, Cancer, 32, 302, 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2

Lefrak, 1975, Adriamycin (NSC-123127) cardiomyopathy, Cancer Chemother. Rep., 6, 203

Minow, 1975, Adriamycin cardiomyopathy—an overview with determination of risk factors, Cancer Chemother. Rep., 6, 195

Praga, 1979, Adriamycin cardiotoxicity: a survey of 1273 patients, Cancer Treat. Rep., 62, 931

Dresdale, 1983, Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment or patients with soft tissue sarcomas, Cancer, 52, 51, 10.1002/1097-0142(19830701)52:1<51::AID-CNCR2820520111>3.0.CO;2-#

Von Hoff, 1987, The cardiotoxicity of anticancer agents, Semin. Oncol, 9, 23

Torti, 1983, Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy, Ann. Intern. Med., 99, 745, 10.7326/0003-4819-99-6-745

Alexander, 1979, Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography, N. Engl. J. Med., 300, 278, 10.1056/NEJM197902083000603

Gottdiener, 1981, Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography, Ann. Intern. Med., 94, 430, 10.7326/0003-4819-94-4-430

McKillop, 1983, Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity, Am. Heart J., 106, 1048, 10.1016/0002-8703(83)90651-8

Sonnevald, 1978, Effect of α-tocopherol on the cardiotoxicity of adriamycin in the rat, Cancer Treat. Rep., 62, 1033

Wang, 1980, Effect of vitamin E against adriamycin-induced toxicity in rabbits, Cancer Res., 40, 1022

Breed, 1980, Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit, Cancer Res., 40, 2033

Legha, 1982, Clinical and pharmacological investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity, Ann. N.Y. Acad. Sci., 393, 411, 10.1111/j.1749-6632.1982.tb31279.x

Doroshow, 1981, Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine, J. Clin. Invest., 68, 1053, 10.1172/JCI110328

Myers, 1983, A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by n-acetylcysteine, Semin. Oncol, 10, 53

Chlebowski, 1980, Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity, Cancer Treat. Rep., 64, 47

Green, 1983, Anthracycline cardiotoxicity: a perspective from current clinical studies, 1, 71

Hortobagyi, 1989, Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast cancer, Cancer, 63, 37, 10.1002/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z

Legha, 1982, reduction of doxorubicin toxicity by prolonged continuous intravenous infusion, Ann. Intern. Med., 96, 133, 10.7326/0003-4819-96-2-133

Speyer, 1985, Prospective evaluation of cardiotoxicity during a six hour doxorubicin infusion regimen in women with adenocarcinoma of the breast, Am. J. Med., 78, 555, 10.1016/0002-9343(85)90395-X

Weiss, 1977, Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity, Cancer, 40, 2046, 10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5

Mross, 1992, New anthracycline derivatives: what for?, Eur. J. Cancer, 27, 1542, 10.1016/0277-5379(91)90409-7

Weiss, 1986, Cancer Chemother. Pharmacol., 18, 185, 10.1007/BF00273384

Feldman, 1992, Advanced small cell lung cancer treated with CAV chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard), 11, 296

Mailliard, 1992, Prevention of chronic adriamycin cardiotoxicity with the bisdioxopiperazine dexrazoxane in patients with advanced or metastatic breast cancer, Pro. Am. Soc. Clin. Oncol., 11, 91

Speyer, 1988, Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer, N. Engl. J. Med., 319, 745, 10.1056/NEJM198809223191203

Speyer, 1992, ICRF-187 permits longer treatment with doxorubicin in women with breast cancer, J. Clin. Oncol., 10, 117, 10.1200/JCO.1992.10.1.117

ten Bokkel Huiniuk, 1992, ICRF 187 protects against doxorubicin induced cardiomyopathy, Ann. Oncol., 3, 114

Weisberg, 1992, Dexrazoxane (ADR-529, ICRF-187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity, Pro. Am. Soc. Clin. Oncol., 11, 91

Italian Multicentre Breast Study With Epirubicin, 1988, Phase III randomized study of cyclophosphamide in advanced breast cancer: an Italian multicentre trial, J. Clin. Oncol., 6, 976, 10.1200/JCO.1988.6.6.976

Jain, 1985, A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer, J. Clin. Oncol., 3, 818, 10.1200/JCO.1985.3.6.818

Acton, 1984, Intensely potent morpholinyl anthracyclines, J. Med. Chem., 27, 638, 10.1021/jm00371a014

Westendorf, 1989, Mechanistic aspects of DNA damage by morpholinyl and cyanomorpholinyl anthracyclines, Cancer Res., 49, 5262

Sato, 1991, Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602), Biochem. Pharmacol., 42, 2283, 10.1016/0006-2952(91)90231-S

Sikic, 1985, Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog, Science, 228, 1544, 10.1126/science.4012308

Watanabe, 1991, Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells, Cancer, 51, 157

Villani, 1988, Evaluation of cardiotoxicity of a new anthracycline derivative: 4′-deoxy-4′-iodo-doxorubicin, Invest. New Drugs, 6, 173, 10.1007/BF00175394

Villani, 1991, Early cardiac toxicity of 4′-iodo-4′-deoxydoxorubicin, Eur. J. Cancer, 27, 1601, 10.1016/0277-5379(91)90423-B

Mross, 1990, Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients, Eur. J. Cancer, 26, 1156, 10.1016/0277-5379(90)90276-Y

Myers, 1987, 5-iminodaunomycin: an anthracycline with unique properties, J. Biol. Chem., 262, 11571, 10.1016/S0021-9258(18)60846-4

Creighton, 1969, Antitumour activity in a series of bisDiketopiperazines, Nature, 222, 384, 10.1038/222384a0

Taylor, 1978, Razoxane-induced polyploidy, Br. J. Cancer, 38, 143, 10.1038/bjc.1978.174

Herman, 1972, Prevention of cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart, Pro. Soc. Exp. Biol. Med., 140, 234, 10.3181/00379727-140-36432

Herman, 1974, Modification of some of the toxic effects of daunomycin (NSC-82151) by pretreatment with the antineoplastic agent ICRF-159 (NSC129943), Toxicol. Appl. Pharmacol., 27, 517, 10.1016/0041-008X(74)90031-3

Herman, 1979, Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters, Cancer Treat. Rep., 63, 89

Wang, 1981, Reduction of daunomycin toxicity by razoxane, Br. J. Cancer, 43, 871, 10.1038/bjc.1981.127

Herman, 1985, Comparison of the protective effect of ICRF-187 and structurally related analogues against daunorubicin toxicity in Syrian golden hamsters, Res. Comm. Chem. Path. Pharmacol., 48, 39

Herman, 1981, Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits, Res. Comm. Chem. Path. Pharmacol., 31, 85

Herman, 1981, Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±) -1,2,-bis(dioxopiprazinyl-1-yl) propane (ICRF-187), Cancer Res., 41, 3436

Herman, 1987, Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds, Cancer Treat. Rev., 14, 225, 10.1016/0305-7372(87)90011-9

Herman, 1990, Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced cardiomyopathy, Cancer Treat. Rev., 17, 155, 10.1016/0305-7372(90)90040-M

Herman, 1985, Comparison of the effectiveness of (±) -1,2-bis(dioxopiperazinyl-1-yl) propane (ICRF-187) and n-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles, Cancer Res., 45, 276

Villani, 1990, Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat, Toxicol. Appl. Pharmacol., 102, 292, 10.1016/0041-008X(90)90028-S

Herman, 1988, Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs, Cancer Res., 48, 6918

Alderton, 1992, Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model, Cancer Res., 52, 194

Hassinoff, 1989, The interaction of the cardioprotective agent ICRF-187, its hydrolysis product (ICRF-198) and other chelating agents with Fe(III) and Cu(II) complexes of adriamycin, Agents Actions, 26, 378, 10.1007/BF01967305

Von Hoff, 1981, Phase I study of ICRF-187 using a daily for 3 days schedule, Cancer Treat. Rep., 65, 249

Sobol, 1992, In vitro evidence for direct complexation of ADR-529/ICRF-187 onto an existing ferric-anthracycline complex, Molec. Pharmacol., 41, 8

Holcenberg, 1986, Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults, Cancer Treat. Rep., 70, 703

Koeller, 1981, Phase I trial of ICRF-187 by 48-hour continuous infusion, Cancer Treat. Rep., 65, 459

Liesman, 1981, Phase I evaluation of ICRF-187 in the treatment of patients with advanced malignancy, Cancer, 47, 1959, 10.1002/1097-0142(19810415)47:8<1959::AID-CNCR2820470808>3.0.CO;2-X

Vogel, 1987, Phase I clinical trial and pharmacokinetics of weekly ICRF-187 infusion in patients with solid tumors, Invest. New Drugs, 5, 187, 10.1007/BF00203545

Basser, 1992, Optimal dose ratio of ADR-529 (ICRF-187) and epirubicin, Pro. Am. Soc. Clin. Oncol., 11, 123

Koning, 1991, Cardioxane-ICRF-187: towards anticancer drug specificity through selective toxicity reduction, Cancer Treat. Rev., 18, 1, 10.1016/0305-7372(91)90002-H

Verhoef, 1988, Effects of the cardioprotective agent ADR-529 (ICRF-187) on the antitumour activity of doxorubicin, Pro. Am. Assoc. Cancer Res., 29, 273

Wadler, 1986, Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2,bis(3,5dioxopiperazinyl) propane (ICRF-187) against murine sarcoma S180 cell line, Cancer Res., 46, 1176

Giuliani, 1981, Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin, Cancer Treat. Rep., 65, 267

Morstyn, 1988, Hemopoietic growth factors: a review, Cancer Res., 48, 5624

Sheridan, 1992, Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy, Lancet, 339, 640, 10.1016/0140-6736(92)90795-5